However, we assume that the effect of ibrutinib and zanubrutinib in this breast cancer subtype presumably stems from inhibition of ERBB signalling, as we did not observe any antiproliferative effects of the compounds in HER2-negative cells. The gene discussed is EGFR; the disease is breast carcinoma.